| Allakos Inc (ALLK) | |||
|---|---|---|---|
| 1.06 -0.01 (-0.93%) | 04-22 16:00 | ||
| Open: | 1.06 | Pre. Close: | 1.07 |
| High: | 1.08 | Low: | 1.03 |
| Volume: | 272,495 | Market Cap: | 93(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 1.46 One year: 1.65 |
| Support: | Support1:  Support2: 0.83 |
| Resistance: | Resistance1: 1.25 Resistance2: 1.41 |
| Pivot: | 1.14 |
| Moving Averages: | MA(5): 1.06 MA(20): 1.17 MA(100): 1.76 MA(250): 2.82 |
| MACD: | MACD(12,26): -0.08 Signal(12,26,9): -0.07 |
| %K %D: | %K(14,3): 20.23 %D(3): 18.67 |
| RSI: | RSI(14): 37.01 |
| 52-Week: | High: 5.64 Low: 1 Change(%): -76.9 |
| Average Vol(K): | 3-Month: 771 10-Days: 397 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 1.083 - 1.088 | 1.088 - 1.092 |
| Low: | 1.016 - 1.023 | 1.023 - 1.028 |
| Close: | 1.05 - 1.061 | 1.061 - 1.07 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALLK ] has closed above bottom band by 22.9%. Bollinger Bands are 67.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 87.87 |
| Shares Float (M) | 58.11 |
| % Held by Insiders | 1.96 |
| % Held by Institutions | 87.43 |
| Shares Short (K) | 5560 |
| Shares Short Prior Month (K) | 5500 |
| Stock Financials | |
|---|---|
| EPS | -2.140 |
| Book Value (p.s.) | 1.920 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -38.9 |
| Return on Equity (ttm) | -77.5 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -2.161 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -116.48 |
| Levered Free Cash Flow (M) | -49.35 |
| Stock Valuation | |
|---|---|
| PE Ratio | -0.50 |
| PEG Ratio | -0.03 |
| Price to Book value | 0.55 |
| Price to Sales | |
| Price to Cash Flow | -0.80 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
